Clinical applications of anti-CD20 antibodies. (Q33773139)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

Clinical applications of anti-CD20 antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Oliver W Press

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Gopal AK

series ordinal

1

1 reference

29 July 2017

Press OW

series ordinal

2

1 reference

29 July 2017

1 November 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

445-450

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

CD20: a regulator of cell-cycle progression of B lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

The potential for immunoconjugates in lymphoma therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2899%2990164-6

10.1016/S0022-2143(99)90164-6

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10560936%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference